Inferra AI / Company / BVS
Bioventus Inc.
BVS · Health Care
Last earnings Aug 5, 2026
Key results
Revenuequarter
$147.7 million
revenue of $147.7 million declined 2.4% Organic* revenue advanced 6.2% Second quarter diluted
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Second Quarter 2025 Financial Results For the second quarter, worldwide revenue of $147.7 million declined 2.4% from $151.2 million in the prior-year period.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Organic* revenue increased 6.2% as a result of double digit organic* growth across Surgical Solutions and Restorative Therapies exhibiting the strength of the Company's diverse portfolio.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
EPSquarter
$0.11
Diluted earnings per share of Class A common stock was $0.11 per share, compared to a loss of $0.40 per share in the prior-year period.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Non-GAAP earnings per share of Class A common stock * was $0.21 per share, reflecting an increase of 31% from $0.16 per share in the prior-year period driven by lower interest expense and lower equity-based compensation.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Pain Treatments Global revenuequarter
$73.3 million
Pain Treatments Global revenue of $73.3 million increased 1.5% due to strong growth in demand for Durolane, a differentiated, single-injection hyaluronic acid therapy for knee osteoarthritis, partially offset by lower average selling prices due to a challenging comparison to the prior year.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Surgical Solutions Global revenuequarter
$52.7 million
Surgical Solutions Global revenue of $52.7 million increased 11.4% driven by growth in Ultrasonics as a result of strong volume in the U.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Restorative Therapies Global revenuequarter
$21.6 million
Restorative Therapies Global revenue of $21.6 million decreased 31.6% reflecting the Company s divestiture of its Advanced Rehabilitation Business at the end of 2024.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Gross marginquarter
$102,090 thousand
Gross profit 102,090 103,639 185,146 192,019
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Selling, general, and administrativequarter
$79,110 thousand
Selling, general and administrative expense 79,110 96,668 152,612 175,443
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Operating incomequarter
$18,368 thousand
Operating income (loss) 18,368 (31,473) 23,237 (26,545)
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Net incomequarter
$7,459 thousand
Net income (loss) attributable to Bioventus Inc. $ 7,459 $ (25,682) $ 4,822 $ (30,572)
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q2 2025 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 6, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Segment mix
Business-unit revenue, as stated
Segment revenue figures as stated in the event record.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $147.7 million | — | — |
| EPS | $0.11 | — | — |
| Pain Treatments Global revenue | $73.3 million | — | — |
| Surgical Solutions Global revenue | $52.7 million | — | — |
| Restorative Therapies Global revenue | $21.6 million | — | — |
| Gross margin | $102,090 thousand | — | — |
| Selling, general, and administrative | $79,110 thousand | — | — |
| Operating income | $18,368 thousand | — | — |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 Document Exhibit 99.1 Bioventus Reports Second Quarter Financial Results Q2 reported revenue of $147.7 million declined 2.4% Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period Non-GAAP earnings* of $0.21 per share increased 31% Cash from operations of $25.9 million increased 71% Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, NC August 6, 2025 Bioventus Inc.”
“2025 Financial Guidance Bioventus reiterated its 2025 Financial Guidance provided on May 6, 2025, including an estimated impact of tariffs, which is immaterial at this time.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
Entered into a new Credit Agreement on July 31, 2025 for a $300 million term loan and $100 million revolving credit facility, which provides over $2 million of annual interest expense savings, increased liquidity and debt maturity extension to July 2030.
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our future financial results and liquidity our business strategy, including, without limitation, the impact of the divestiture of our Advanced Rehabilitation Business and impact of our new credit facility on our financial condition and operations the effect of regulatory approvals our ability to commercialize our products and timeframe sales trends estimated market opportunities, position and growth.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
Event summary
Second Quarter 2025 Financial Results For the second quarter, worldwide revenue of $147.7 million declined 2.4% from $151.2 million in the prior-year period
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “htm EX-99.1 Document Exhibit 99.1 Bioventus Reports Second Quarter Financial Results Q2 reported revenue of $147.7 million declined 2.4% Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period Non-GAAP earnings* of $0.21 per share increased 31% Cash from operations of $25.9 million increased 71% Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, NC August 6, 2025 Bioventus Inc.”
Revenue — Raised (“increased”)
“htm EX-99.1 Document Exhibit 99.1 Bioventus Reports Second Quarter Financial Results Q2 reported revenue of $147.7 million declined 2.4% Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period Non-GAAP earnings* of $0.21 per share increased 31% Cash from operations of $25.9 million increased 71% Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, NC August 6, 2025 Bioventus Inc.”
Company outlook — Reiterated (“reiterated”)
“2025 Financial Guidance Bioventus reiterated its 2025 Financial Guidance provided on May 6, 2025, including an estimated impact of tariffs, which is immaterial at this time.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Entered into a new Credit Agreement on July 31, 2025 for a $300 million term loan and $100 million revolving credit facility, which provides over $2 million of annual interest expense savings, increased liquidity and debt maturity extension to July 2030.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our future financial results and liquidity our business strategy, including, without limitation, the impact of the divestiture of our Advanced Rehabilitation Business and impact of our new credit facility on our financial condition and operations the effect of regulatory approvals our ability to commercialize our products and timeframe sales trends estimated market opportunities, position and growth.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Activity in 2024 is attributable to advisory fees and debt amendment related costs related to our Amended 2019 Credit Agreement.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Financial Instruments Long-term debt consisted of the following as of: 2025 Credit Agreement June 27, 2026 December 31, 2025 2025 Term Loan $ 250,500 $ 296,250 Less: Current portion of long-term debt ( 18,750 ) ( 15,000 ) Unamortized debt issuance cost ( 508 ) ( 570 ) Unamortized discount ( 1,540 ) ( 1,729 ) $ 229,702 $ 278,951 2025 Credit Agreement On July 31, 2025, the Company entered into a Credit Agreement (the 2025 Credit Agreement ) with Wells Fargo Bank, National Association, and a syndicate of financial institutions and other entities (collectively, the Lenders ).
SEC original ↗Bioventus Inc. — 10-Q Quarterly report10-QAug 5, 2026
The 2025 Credit Agreement consists of a $ 300,000 term loan facility (the 2025 Term Loan ) and a $ 100,000 revolving credit facility (the 2025 Revolver and, together with the 2025 Term Loan, the 2025 Term Loan Facilities ).
SEC original ↗Bioventus Inc. — 10-Q Quarterly report10-QAug 5, 2026
Proceeds from the 2025 Term Loan, borrowings of $ 30,000 under the 2025 Revolver, and $ 2,562 in available cash were used to repay the outstanding balance under the 2019 Credit and Guaranty Agreement, as amended, which totaled $ 332,562 as of July 31, 2025.
SEC original ↗Bioventus Inc. — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
Recent Business Highlights Bioventus continues to advance its strategic priorities with key achievements, including the following Obtained FDA 510(k) clearance for TalisMann, an innovative Peripheral Nerve Stimulation (PNS) system engineered to deliver long-term relief from chronic nerve pain, in July 2025.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
, the combination of TalisMann and StimTrial represents an exciting expansion opportunity to advance non-opioid, minimally invasive solutions for chronic pain management.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our future financial results and liquidity our business strategy, including, without limitation, the impact of the divestiture of our Advanced Rehabilitation Business and impact of our new credit facility on our financial condition and operations the effect of regulatory approvals our ability to commercialize our products and timeframe sales trends estimated market opportunities, position and growth.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
(i) Other items includes charges associated with strategic transactions, including potential acquisitions or divestitures and a transformative project to redesign systems and information processing.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
During the three and six months ended June 29, 2024, other items primarily consisted of (i) strategic transaction expenses of $1.8 million and $2.3 million, respectively, primarily related to Advanced Rehabilitation Business divestiture expenses and (ii) transformative project costs of $0.5 million and $1.3 million, respectively.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Risks & headwinds
2025 Financial Guidance Bioventus reiterated its 2025 Financial Guidance provided on May 6, 2025, including an estimated impact of tariffs, which is immaterial at this time.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The guidance assumes the Company will continue to successfully offset the combined $5 million related to foreign exchange expense, which occurred throughout the first half of the year, and the full year expected impact of current tariffs.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
These items include acquisition and divestiture related costs, certain shareholder litigation costs, impairment of assets, restructuring and succession charges, equity-based compensation expense, financial restructuring costs and other items.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
These items include depreciation and amortization, acquisition and divestiture related costs, certain shareholder litigation costs, impairment of assets, restructuring and succession charges, financial restructuring costs and other items.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
These items include depreciation and amortization, acquisition and divestiture related costs, certain shareholder litigation costs, restructuring and succession charges, impairment of assets, financial restructuring costs, other items and the tax effect of adjusting items.
SEC original ↗Bioventus Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q2 2026
- 8-KBVS
Aug 5, 2026
- 10-QBVS
Aug 5, 2026
- Q1 2026
- 8-KBVS
Jun 4, 2026
- 8-KBVS
May 21, 2026
- 8-KBVS
May 6, 2026
- 10-QBVS
May 6, 2026
- Q4 2025
- 8-KBVS
Mar 5, 2026
- 10-KBVS
Mar 5, 2026
- Q3 2025
- 8-KBVS
Nov 17, 2025
- 8-KBVS
Nov 4, 2025
- 10-QBVS
Nov 4, 2025
- Q2 2025
- 8-KBVS
Aug 6, 2025
- 10-QBVS
Aug 6, 2025
- 8-KBVS
Aug 4, 2025
- 8-KBVS
Jul 31, 2025
- Q1 2025
- 8-KBVS
Jun 4, 2025
- 8-KBVS
May 6, 2025
- 10-QBVS
May 6, 2025
- Q4 2024
- 8-KBVS
Mar 11, 2025
- 10-KBVS
Mar 11, 2025
- 8-KBVS
Jan 3, 2025
- Q3 2024
- 8-KBVS
Nov 5, 2024
- 10-QBVS
Nov 5, 2024
- 8-KBVS
Oct 4, 2024
- Q2 2024
- 8-KBVS
Aug 6, 2024
- 10-QBVS
Aug 6, 2024
- 8-KBVS
Jul 19, 2024
- Q1 2024
- 8-KBVS
Jun 21, 2024
- 8-KBVS
Jun 17, 2024
- 10-QBVS
May 7, 2024
Earnings releases
9 documentsPresentations
0 documentsNo presentations for Bioventus Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Bioventus Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.